Carboplatin and paclitaxel in advanced or metastatic endometrial cancer
| Autor: | George Papaxoinis, Asimina Gaglia, D. Kassanos, P. Gouveris, J. Panayiotidis, Amanda Psyrri, Eirini Pectasides, Dimitrios Pectasides, T. Economopoulos, Anna Koumarianou, George Fountzilas, Constantinos Sykiotis, Nikolaos Xiros |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult medicine.medical_specialty Paclitaxel medicine.medical_treatment Antineoplastic Agents Kaplan-Meier Estimate Neutropenia Gastroenterology Disease-Free Survival Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Aged Aged 80 and over Chemotherapy business.industry Endometrial cancer Area under the curve Obstetrics and Gynecology Middle Aged medicine.disease Antineoplastic Agents Phytogenic Endometrial Neoplasms Treatment Outcome chemistry Toxicity Disease Progression Female Neoplasm Recurrence Local business Febrile neutropenia |
| Zdroj: | Gynecologic oncology. 109(2) |
| ISSN: | 1095-6859 |
| Popis: | Objectives The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent endometrial carcinoma. Methods Forty-seven eligible patients with measurable advanced or recurrent endometrial carcinoma were treated with carboplatin [area under the curve (AUC) 5] and paclitaxel 175 mg/m(2) every 3 weeks for 6-9 cycles or until disease progression or unacceptable toxicity. Results There were 10 complete responses (CRs) (21%) and 19 partial responses (PRs) (41%) for an overall response rate (RR) of 62% (29 patients) (95% confidence interval [CI], 47-76%). The median progression-free survival (PFS) was 15 months (95% CI, 7.3-22.7 months) and the median overall survival (OS) was 25 months (95% CI, 19.0-31.0 months). No difference was found in RR and OS in patients with primary advanced disease and those with recurrent tumors. Similarly, no difference was found in PFS and OS for patients with serous/clear tumors and those with endometrioid tumors. Toxicity was generally mild except for myelotoxicity. Neutropenia grade 3/4 was recorded in 36% of patients and 6% experienced febrile neutropenia. One patient each developed grade 4 thrombocytopenia and anemia. Grade 3 sensory neuropathy was recorded in 6% of patients. Conclusion The combination of carboplatin and paclitaxel appears to have activity in advanced or recurrent endometrial carcinoma with an acceptable toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect